Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

2.0K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.0K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.2K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.2K
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

1.7K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.7K
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

1.9K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential new standard of care for resectable gastro-oesophageal adenocarcinoma in Asia.

Nature reviews. Clinical oncology·2026
Same author

From ASCO 2026.

Nature reviews. Clinical oncology·2026
Same author

Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer.

Nature reviews. Clinical oncology·2026
Same author

Lisocabtagene maraleucel has high efficacy in R/R MZL.

Nature reviews. Clinical oncology·2026
Same author

CDK4/6 inhibition provides additional efficacy in HER2<sup>+</sup>, HR<sup>+</sup> breast cancer.

Nature reviews. Clinical oncology·2026
Same author

MajesTEC results with teclistamab in relapsed and/or refractory multiple myeloma.

Nature reviews. Clinical oncology·2026

Related Experiment Video

Updated: Feb 15, 2026

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

17.6K

Immunotherapy: Targeting MDSCs with LXR agonists

David Killock

    Nature Reviews. Clinical Oncology
    |February 1, 2018
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
    06:51

    Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

    Published on: December 17, 2019

    16.0K
    Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
    08:40

    Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

    Published on: August 1, 2013

    18.7K

    Related Experiment Videos

    Last Updated: Feb 15, 2026

    Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
    16:56

    Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

    Published on: August 30, 2014

    17.6K
    Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
    06:51

    Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

    Published on: December 17, 2019

    16.0K
    Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
    08:40

    Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

    Published on: August 1, 2013

    18.7K